Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing. The Series A financing will support comp

June 2, 2026 -- Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will be used to advance Tavo's pipeline of innovative therapies targeting glaucoma and retinal disease. In conjunction with the financing, Tavo Biotherapeutics also announced the appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer, t

Anthropic has raised $65 billion in Series H funding, bringing its post-money valuation to $965 billion and surpassing OpenAI to become the world's highest-valued private AI company. Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, D1 Capital Partners, GIC, ICONIQ and XN co-led the round. Other investors in the round include AMP PBC, Baillie Gifford, Blackstone, Brookfield, D.E. Shaw Ventures, DST Global, Fidelity Management & Research Company, General Catalyst,

Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years May 28, 2026 -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that it has entered into a definitive financing agreement with an institutional investor providing for

May 27, 2026 -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million. In this private pla

Grant marks Alveo's entry into vaccine manufacturing market, extending its molecular detection platform beyond infectious disease diagnostics. May 26, 2026 -- Alveo Technologies, Inc. (Alveo), a leader in portable molecular sensing solutions, today announced it has been awarded a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore how its platform, already in use around the globe for pathogen detection, can be used in vaccine manufacturing. The award marks Alveo's e

Strengthening balance sheet on path to Nasdaq uplisting May 22, 2026 -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggr

Sartorius, a life sciences equipment and services company headquartered in Göttingen, Germany, has opened a new competence center in Freiburg, Germany, dedicated to the development and production of quality-critical materials for the cell and gene therapy market, including cytokines and growth factors. The facility covers approximately 18,000 square meters — roughly 194,000 square feet — and can accommodate up to 180 employees, according to the announcement. The site meets GMP quality standards

In the sprawling metropolis of Houston, a new biotech has emerged to tackle the biology underlying a lung disease that has no clear cause. Oorja Bio launched yesterday afternoon with $30 million and an in-licensed, novel approach to treat idiopathic pulmonary fibrosis. Oorja’s funds come from founding investor Westlake BioPartners, according to the May 19 release. The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining the structure and sta

Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of drug targets, continuing the biotech’s rapid embrace of AI in drug discovery and development. Delaware-based Incyte partnered with Genesis in February 2025. That deal, which included a $30 million upfront payment, positioned the companies to collaborate on two targets and gave Incyte the option to nominate a third target for a predetermined fee. Genesis has now secured an expanded a